Literature DB >> 28105362

Pre-treatment serum inflammatory cytokines as survival predictors of patients with nasopharyngeal carcinoma receiving chemoradiotherapy.

Adel F Al-Kholy1, Omminea A Abdullah1, Mamdouh Z Abadier1, Manal M Hassaan2, Mohamed F Shindy3, Dalia M Nor El-Dien4, Ali Hasaneen5.   

Abstract

The present study aimed to examine the predictability of pre-treatment serum levels of interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α for determining the outcome of patients with nasopharyngeal carcinoma (NPC) assigned for chemoradiotherapy. A total of 35 patients with NPC were subjected to clinical examination and evaluation of performance status using Karnofsky scoring. Nasopharyngoscopy was performed for evaluation and to obtain a biopsy. Blood samples were obtained pre- and post-treatment for polymerase chain reaction quantitative estimation of Epstein-Barr virus (EBV) DNA plasma load and enzyme-linked immunosorbent assay for estimation of serum cytokines. All patients received chemoradiotherapy and were followed-up for 2 years. Cervical lymphadenopathy and recurrent attacks of epistaxis are the most common presenting symptoms. Treatment significantly decreased pre-treatment plasma EBV DNA load and serum levels of IL-6 and TNF-α, and increased serum IL-1β levels. Clinical staging and EBV DNA plasma load revealed positively significant correlation with pre-treatment serum levels of both IL-6 and TNF-α, while revealed negative significant correlation with serum IL-1β levels. The 2-year survival rate was negatively significantly correlated with pre-treatment levels of IL-6 and TNF-α, and EBV DNA viral load, while it was positively significantly correlated with pre-treatment performance scores and serum IL-1β levels. Statistical analyses defined high pre-treatment serum IL-6 levels as a significant specific predictor for high mortality rate. It was demonstrated that NPC was associated with high pre-treatment plasma EBV DNA load and serum cytokines, and chemoradiotherapy significantly reduced these high levels. High pre-treatment serum IL-6 level was a significant specific predictor for high mortality rate. Increased post-treatment serum levels of IL-1β indicated good therapeutic response and most probably a high survival rate.

Entities:  

Keywords:  chemoradiotherapy; inflammatory cytokines; nasopharyngeal carcinoma; plasma EB viral load; survival rate

Year:  2016        PMID: 28105362      PMCID: PMC5228416          DOI: 10.3892/mco.2016.1041

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  29 in total

1.  Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells.

Authors:  Angela Kwok Fung Lo; Kwok Wai Lo; Sai Wah Tsao; Hing Lok Wong; Jan Wai Ying Hui; Ka Fai To; Diane S Hayward; Yiu Loon Chui; Yu Lung Lau; Kenzo Takada; Dolly P Huang
Journal:  Neoplasia       Date:  2006-03       Impact factor: 5.715

Review 2.  Role of EBERs in the pathogenesis of EBV infection.

Authors:  Dai Iwakiri; Kenzo Takada
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

3.  Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients.

Authors:  E-M Reitter; C Ay; A Kaider; R Pirker; C Zielinski; G Zlabinger; I Pabinger
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

4.  Prognostic role of serum cytokines in patients with nasopharyngeal carcinoma.

Authors:  Ke Lu; Xinglai Feng; Qinghua Deng; Liming Sheng; Peng Liu; Shenhua Xu; Dan Su
Journal:  Onkologie       Date:  2012-08-13

5.  Assaying tumor necrosis factor concentrations in human serum. A WHO International Collaborative study.

Authors:  S de Kossodo; V Houba; G E Grau
Journal:  J Immunol Methods       Date:  1995-05-11       Impact factor: 2.303

6.  Upregulation of interleukin-1 by Epstein-Barr virus latent membrane protein 1 and its possible role in nasopharyngeal carcinoma cell growth.

Authors:  Yu-Tzu Huang; Mei-Ying Liu; Ching-Hwa Tsai; Te-Huei Yeh
Journal:  Head Neck       Date:  2010-07       Impact factor: 3.147

7.  Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion.

Authors:  Cheng-Hsun Ho; Chi-Long Chen; Wing-Yin Li; Chi-Ju Chen
Journal:  Carcinogenesis       Date:  2009-05-29       Impact factor: 4.944

8.  Constitutive interferon-inducible protein 16-inflammasome activation during Epstein-Barr virus latency I, II, and III in B and epithelial cells.

Authors:  Mairaj Ahmed Ansari; Vivek Vikram Singh; Sujoy Dutta; Mohanan Valiya Veettil; Dipanjan Dutta; Leela Chikoti; Jie Lu; David Everly; Bala Chandran
Journal:  J Virol       Date:  2013-05-29       Impact factor: 5.103

9.  Tumour inflammasome-derived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma.

Authors:  Lih-Chyang Chen; Li-Jie Wang; Nang-Ming Tsang; David M Ojcius; Chia-Chun Chen; Chun-Nan Ouyang; Chuen Hsueh; Ying Liang; Kai-Ping Chang; Chiu-Chin Chen; Yu-Sun Chang
Journal:  EMBO Mol Med       Date:  2012-10-15       Impact factor: 12.137

Review 10.  Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma.

Authors:  Susanna Hilda Hutajulu; Johan Kurnianda; I Bing Tan; Jaap M Middeldorp
Journal:  Ther Clin Risk Manag       Date:  2014-09-05       Impact factor: 2.423

View more
  2 in total

1.  Role of Pretreatment Hemoglobin-to-Platelet Ratio in Predicting Survival Outcome of Locally Advanced Nasopharyngeal Carcinoma Patients.

Authors:  Cosphiadi Irawan; Andhika Rachman; Puji Rahman; Arif Mansjoer
Journal:  J Cancer Epidemiol       Date:  2021-10-30

Review 2.  Nasopharyngeal Carcinoma and Its Microenvironment: Past, Current, and Future Perspectives.

Authors:  Zhi Yi Su; Pui Yan Siak; Chee-Onn Leong; Shiau-Chuen Cheah
Journal:  Front Oncol       Date:  2022-03-02       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.